The FDA Has Accepted And Granted Priority Review AstraZeneca's Supplemental New Drug Application For Calquence (Acalabrutinib) For Previously Untreated Mantle Cell Lymphoma, The FDA Action Date Is Anticipated During Q1 Of 2025
The FDA Has Accepted And Granted Priority Review AstraZeneca's Supplemental New Drug Application For Calquence (Acalabrutinib) For Previously Untreated Mantle Cell Lymphoma, The FDA Action Date Is Anticipated During Q1 Of 2025
美國食品和藥物管理局已接受並優先審查阿斯利康針對未曾治療過的瀰漫大B細胞淋巴瘤的Calquence（阿卡曲替尼）補充新藥申請，FDA行動日期預計在2025年第一季度。
The FDA Has Accepted And Granted Priority Review AstraZeneca's Supplemental New Drug Application For Calquence (Acalabrutinib) For Previously Untreated Mantle Cell Lymphoma, The FDA Action Date Is Anticipated During Q1 Of 2025
美國食品和藥物管理局已接受並優先審查阿斯利康針對未曾治療過的瀰漫大B細胞淋巴瘤的Calquence（阿卡曲替尼）補充新藥申請，FDA行動日期預計在2025年第一季度。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。